Seon-Jeong Park, and Jong-Soo Lee *
Department of Biomedicine and Biotechnology, Paichai University, Daejeon 35345, Korea.
Correspondence to biotech8@pcu.ac.kr
Korean Journal of Mycology (Kor J Mycol) March, 2022, 50(1):31-40.
https://doi.org/10.4489/KJM.20220002
Accepted: January 22, 2022; Revised: February 21, 2022; Received: January 27, 2022
Published: March, 2022.
© 2022 THE KOREAN SOCIETY OF MYCOLOGY.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
We aimed to produce a potent β-glucuronidase inhibitor from wild yeast that could inactivate toxic substances in the colon. Culture supernatants and cell-free extracts of non-pathogenic wild yeasts were prepared and their β-glucuronidase inhibitory activities were measured. Cell-free extract from Candida oleophila WP5-19-1 showed the highest β-glucuronidase inhibitory activity (49.0%). The β-glucuronidase inhibitor was maximally produced (IC50 value; 8.4 mg) when C. oleophila WP5-19-1 was cultured in potato dextrose medium containing 5% dextrose (initial pH; 6.0) at 30℃ for 24 hours. β-glucuronidase inhibitor of C. oleophila WP5-19-1 was partially purified by trypsin hydrolysis, ultrafiltration (3 kDa), and Sephadex G-50 filtration. The partially purified β-glucuronidase inhibitor was stable from 30℃ to 60℃ and at pH 6.0 9.0, and showed residual inhibitory activity of about 80%.
β-glucuronidase inhibitor, Candida oleophila WP5-19-1, Non-pathogenic wild yeast, Partial purification, Probiotics